SQ 26533

structure given in first source

Also Known As:

2,2'-(5-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-2,3-naphthalenediyl)bis(oxy)bis(N,N-dipropylacetamide); SQ 26,533; SQ-26,533

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        SQ 26533: 1
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - SQ 26533: 1

Related Diseases

1.	Ventricular Premature Complexes (Premature Ventricular Contraction) 04/01/1986 - "SQ 26,533 (2.5 mg/kg i.v.) given 1 hr before occlusion significantly reduced (81%) ventricular ectopic beats during acute occlusion and four of five animals (80%) survived left anterior descending artery reperfusion, unlike saline controls (100% mortality). " 04/01/1986 - "SQ 26,533 infused at 50 micrograms/kg/min for 45 min significantly reduced (78%) the incidence of ventricular ectopic beats during the 30-min ligation of LCX. " 04/01/1986 - "SQ 26,533 (2.5 mg/kg every 90 min) given 50 min after LCX occlusion not only resulted in a significant reduction (91%) of postreperfusion ventricular ectopic beats for the entire 5-hr observation period but also significantly reduced (42%) the infarct size at 24 hr. Antiarrhythmic doses of SQ 26,533 caused minimal hemodynamic changes, except for a marked decrease in heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)"
2.	Infarction (Infarctions) 04/01/1986 - "The antiarrhythmic, antifibrillatory activities and the ability of SQ 26,533 to reduce infarct size were investigated in the canine models of reperfusion arrhythmias. " 04/01/1986 - "Effects of SQ 26,533 on reperfusion arrhythmias, ST-segment elevation and on infarct size in anesthetized dogs." 04/01/1986 - "SQ 26,533 (2.5 mg/kg every 90 min) given 50 min after LCX occlusion not only resulted in a significant reduction (91%) of postreperfusion ventricular ectopic beats for the entire 5-hr observation period but also significantly reduced (42%) the infarct size at 24 hr. Antiarrhythmic doses of SQ 26,533 caused minimal hemodynamic changes, except for a marked decrease in heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)"

Related Therapies and Procedures

1.	Ligation